Clinical trial
Abilify as an Adjunctive Treatment for Refractory Depression
NCT00220636 · St. Luke's-Roosevelt Hospital Center, Other · Completed
Key facts
| NCT number | NCT00220636 |
|---|---|
| Title | Abilify as an Adjunctive Treatment for Refractory Depression |
| Official title | Abilify (Aripiprazole) as an Adjunctive Treatment for Refractory Unipolar Depression |
| Lead sponsor | St. Luke's-Roosevelt Hospital Center, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 15 |
| Start date | Mar 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Sep 22, 2005 |
| Last update posted | May 26, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: